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Summary Gemcitabine (dFdC), a deoxycitidine nucleoside analogue, inhibits DNA synthesis and repair of radiation-induced chromosome
breaks in vitro, radiosensitizes various human and mouse cells in vitro and shows clinical activity in several tumours. Limited data are
however available on the effect of dFdC on normal tissue radiotolerance and on factors associated with dFdC's radiosensitization in vivo. The
purpose of this study was to determine the effect of dFdC on mouse jejunum radiosensitization and to investigate the kinetics of DNA
synthesis inhibition and cell cycle redistribution in the jejunal crypts as surrogates of radiosensitization in vivo. For assessment of jejunum
tolerance, the mice were irradiated on the whole body with 6OCo gamma rays (3.5-18 Gy single dose) with or without prior administration of
dFdC (150 mg kg-'). Jejunum tolerance was evaluated by the number of regenerated crypts per circumference at 86 h after irradiation. For
pharmacodynamic studies, dFdC (150 or 600 mg kg-') was given i.p. and jejunum was harvested at various times (0-48 h), preceded by a
pulse BrdUrd labelling. Labelled cells were detected by immunohistochemistry on paraffin-embedded sections. DNA synthesis was inhibited
within 3 h after dFdC administration. After an early wave of apoptosis (3-6 h), DNA synthesis recovered by 6 h, and crypt cells became
synchronized. At 48 h, the labelling index returned almost to background level. At a level of 40 regenerated crypts, radiosensitization was
observed for a 3 h time interval (dose modification factor of 1.3) and was associated with DNA synthesis inhibition, whereas a slight
radioprotection was observed for a 48-h time interval (dose modification factor of 0.9) when DNA synthesis has reinitiated. In conclusion,
dFdC altered the radioresponse of the mouse jejunum in a schedule-dependent fashion. Our data tend to support the hypothesis that DNA
synthesis inhibition and cell cycle redistribution are surrogates for radiosensitization. More data points are however required before a definite
conclusion can be drawn.
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Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is a deoxycyti-
dine nucleoside analogue that has a marked effect on several
enzymes involved in DNA synthesis and repair (Plunkett et al;
1995; Peters, 1996). Like other nucleoside analogues, dFdC is a
prodrug that requires intracellular activation by phosphorylation
into its active triphosphate dFdCTP form. dFdCTP is incorporated
into DNA at the penultimate position and blocks further
elongation ofthe DNA strand. An array ofself-potentiation mech-
anisms have been identified and they likely contribute to the high
accumulation and low elimination of the intracellular dFdCTP
(Heinemann et al, 1992). Among them, is the inhibition of ribo-
nucleotide reductase by the diphosphate form dFdCDP, which
decreases the concentration of dCTP and thus facilitates dFdCTP
incorporation into DNA. Gemcitabine can also be incorporated
into RNA (Ruiz Van Haperen et al, 1993) and can induce apoptosis
(Huang, 1992; Bouffard, 1995; Gruber et al, 1996). Gemcitabine
has been tested in various phase I and II trials, and promising
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clinical activity has been reported in non-small-cell lung cancer,
pancreatic, ovarian, breast, bladder, and head and neck tumours
(Guchelaar et al, 1996).
dFdC has been evaluated for its capacity to increase thelethality
induced by various clastogenic agents and, in particular, ionizing
radiation. It is known that efficient repair of radiation-induced
genomic damage, tumourclonogen proliferation between radiation
fractions, and tumor hypoxia constitute major causes of failure to
radiotherapy treatment (Weichselbaum et al, 1986; Withers, 1993;
Nordsmark et al, 1996). dFdC is an attractive candidate for
enhancing radiation response for several reasons. First, as an
inhibitor of DNA replication dFdC also has the potential for
inhibiting DNArepair after irradiation. Indeed, DNA synthesis and
DNA repair have been reported to share some common enzymatic
pathways (Downes et al, 1983). Second, dFdC, as an inhibitor of
DNA synthesis, can serve to slow tumour clonogen regrowth
between radiation dose fractions and hence overcome the detri-
mental effect of tumour clonogen proliferation. Third, because of
its cytotoxic activity in proliferating cells (probably through apo-
ptosis), dFdC may induce more rapid cell loss and consequently
serve to enhance the rate of reoxygenation during a fractionated
radiotherapy treatment, as documented with other cytotoxic agents
(Milas et al, 1995). This phenomenon would help to overcome the
detrimental impact ofhypoxia on tumourradioresponse.
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In vitro, it has been observed that dFdC inhibited the repair of
chromosome breaks after irradiation in quiescent normal human
fibroblasts (Huang, 1995). In various cell lines, radiosensitization
for cell lethality has been reported, with dose modification factors
ranging from 1.2 to 3.0 depending on the cell lines, drug concen-
tration and timing ofadministration (Rockwell, 1992; Mullen et al,
1994; Shewach et al, 1994; Shewach, 1995; Lawrence et al, 1995,
1996; Gregoire et al, 1996; Rosier et al 1997]. In vivo radiosensiti-
zation has also been reported in a murine sarcoma with regrowth
delay enhancements in the range of 1.1-2.0, depending on the
schedule of drug administration in relation to irradiation
(Hittelman et al, 1996).
Little is known about the factors involved in dFdC's radiosensi-
tization. In vitro, it has been reported that radiosensitization of HT-
29 colorectal carcinoma cells was associated to some extend to
intracellular dFdCTP accumulation, but that the level of dATP
depletion was the most important factor for radiosensitization
(Shewach et al, 1994). In this study, both dFdCTP accumulation
and dATP depletion paralleled DNA synthesis inhibition. Similar
data were reported in BxPC-3 and Panc-1 pancreatic carcinoma
cell lines (Lawrence et al, 1996). However, it has been shown
recently that dFdC has no effect on the radiation response of a
human D54 glioblastoma cell line, although intracellular dATP
depletion was decreased by more than 90% (Ostruszka, 1997).
Cell cycle redistribution is another possible factor thought to be
implicated in radiosensitization by dFdC. In vitro, it has also been
shown that dFdC induced a G -S block in HT-29 cells and, as cells
at the G1/S boundary are slightly more radiosensitive, this effect
was thought to account, to some extent, for the radiosensitization
observed in these cells (Shewach, 1995).
While the data mentioned above demonstrate the promise of
combined dFdC and radiotherapy treatment, no data are however
available on the effect of dFdC on the tolerance of normal tissues
to irradiation. Combining dFdC and radiotherapy will only bring a
therapeutic advantage if dFdC's enhancement is lower in normal
tissues than in tumours. In the present paper, we sought to deter-
mine the effect of dFdC on mouse jejunum radiosensitization.
Mousejejunum is an early reacting tissue that represents an appro-
priate model for the study ofnormal mucosa reaction after irradia-
tion. Such study could thus bring relevant data for the scheduling
ofdFdC and irradiation in the treatment ofhead and neck, pancre-
atic and colorectal carcinomas. In addition, the present paper
also attempted to define surrogates for mousejejunum radiosensi-
tization, i.e. kinetics of DNA synthesis inhibition and cell cycle
redistribution in thejejunal crypt cells.
Our data indicate that dFdC decreased the mouse jejunum toler-
ance to single-dose radiation in a drug administration schedule-
dependent manner. Radiosensitization was observed for a 3-h time
interval between drug administration and irradiation when DNA
synthesis was shutoff, whereas a slightradioprotection was observed
for a 48-h time interval when DNA synthesis has reinitiated.
MATERIALS AND METHODS
Animals
Ten- to twelve-week-old male C3H/HeOUJco (pharmacody-
namics experiments) or C3H/HeNHsd (intestinal crypt regenera-
tion experiments) mice were housed 3 or 4 per cage and were
given food and water ad libitum for the duration of the experi-
ments. Animals were maintained in a facility approved by the
c
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Figure 1 Effect of dFdC (150 mg kg-') on the tolerance of mouse jejunum to
single-dose irradiation. Mice were treated by irradiation alone (0), dFdC
given 3 h before irradiation (-) or dFdC given 48 h before irradiation (A).
Three days and 14 h after irradiation, mice were killed, the jejunum was
removed, fixed in Bouin, paraffin embedded and stained with trichrome. The
number of regenerated crypts per circumference was counted in two different
sections per mouse. Each point is the average of 6 or 7 mice.
Dose-response curves were fitted by a least square regression analysis
Belgian Ministry ofAgriculture in accordance with current regula-
tions and standards.
Gemcitabine
2',2'-Difluorodeoxycytidine was generously supplied by Eli Lilly
(Indianapolis, IN, USA). Before each experiment, the drug was
reconstituted in 1 x phosphate-buffered saline (PBS), adjusted to a
pH of7.0 ± 0.2 with sodium hydroxide solution, filtered through a
0.45-gm Acrodisc filter and stored at 4°C until use. The concen-
trations ofgemcitabine were adjusted to inject0.02 or0.015 ml g-I
mouse body weight. Gemcitabine was administered i.p. at room
temperature.
Intestinal crypt regeneration assay
Thejejunum crypt survival assay developed by Withers and Elkind
(1970) was used to determine the radiation toxicity to mouse
intestinal mucosa. Briefly, mice were whole-body irradiated with
6OCo gamma rays at a dose rate of 1.02 Gy min-m with or without
prior gemcitabine administration. For experiments with radiation
alone, six radiation doses each including six animals were used.
For combined gemcitabine and radiation treatment, eight radiation
doses each including seven animals were used. Three days and
14 h after irradiation, mice were killed by cervical dislocation and
afew centimetres ofjejunum was removed fromthe angle ofTreitz
and fixed in Bouin. After paraffin embedding, 4-g transverse
sections of the jejunum were cut and stained with trichrome. The
number of regenerated crypts per jejunum circumference was
counted in two different sections per mouse. Only crypts with ten
or more cells were counted. Dose-response curves were fitted by a
least square regression analysis. Dose modification factors (DMFs)
were calculated at a level of40 regenerated crypts. Ninety-five per
cent confidence limits on the DMF were calculated by the method
described by Van Dam (1984). Details of the method can be
obtained from the first author ofthe present paper.
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Pharmacodynamics of DNA synthesis inhibition
DNA synthesis in jejunum crypt cells was monitored at various
times after gemcitabine administration by in vivo labelling with
BrdUrd (Sigma Chemical, St Louis, MO, USA). BrdUrd was
dissolved in 1 x PBS at a concentration of 6 mg ml', filtered
through a 0.45-gm Acrodisc filter and stored at 4°C until use.
BrdUrd was injected i.p. at a dose of 60 mg kg-', 30 min before
killing the mice by cervical dislocation. A few centimetres of
jejunum was removed from the angle ofTreitz and fixed in neutral-
buffered 10% formalin. After embedding, 4-j transverse sections
of the jejunum were cut and processed for immunohistochemical
detection of cells with BrdUrd-substituted DNA. Labelled and
unlabelled crypt cells were counted on transversal sections of the
jejunal crypts. The labelling index was determined as the numberof
labelled cells divided by the total number of cells. Two sections
were scored per mouse. Foreach time point, three mice were used.
Immunohistochemical detection of cells with
BrdUrd-substituted DNA
Cells labelled in vivo with BrdUrd were detected on embedded
tumour sections as previously described (Gregoire et al, 1994a).
Briefly, 4-g paraffin sections were incubated overnight in an oven
at 58°C, dewaxed in xylene (Sigma Chemical, St Louis, MO,
USA) baths and progressively hydrated in ethanol (UCB, Brussels,
Belgium) solutions. Endogenous peroxidase was inactivated by
immersing the slides in 0.75% hydrogen peroxide (E Merck,
Darmstadt, Germany) in methanol (UCB, Brussels, Belgium). The
slides were digested with 0.05% pepsin A (Sigma Chemical) (w/v)
Figure 2 Light micrograph (400x) ofjejunal crypt sections after immunohistochemical staining of BrdUrd-labelled nuclei. Mice were treated with dFdC (150 mg kg-')
and, at 0, 3.5, 12.5, 18, 24 and 48 h after drug administration, jejunum was harvested and fixed in 10% neutral-buffered formalin. S-phase cells were labelled with
BrdUrd (60 mg kg-') 30 min before tissue harvest. Sections were processed for immunohistochemical detection of BrdUrd-labelled nuclei using a specific antibody for
BrdUrd-containing DNA. Apoptotic figures (arrowheads) were visualized at 3.5 h. Mitotic figures (arrowheads) were observed at 18 h
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Table 1 Effect of dFdC on the pharmacodynamics of DNA synthesis
inhibition in mouse jejunum crypt cells
Time after dFdC Labelling index (%)
administration (h)
150 mg kg-' dFdC 600 mg kg-1 dFdC
0 26.8+ 2.0a 39.1 + 8.9
3.5 0.0 1.2+1.2
6 0.0 2.1 ± 1.4
12 - 29.7+ 14.8
12.5 44.1 ± 8.4 -
18 20.0 ± 14.8 13.8 ± 7.8
24 63.3±7.1 13.3±2.3
36 50.3 + 6.0 62.5 ± 8.6
48 34.2 ± 9.0 44.5 ± 11.8
aAverage s.e.m. Mice were given 150 mg kg-' or 600 mg kg-' dFdC and, at
various times after drug administration, jejunum was harvested and fixed in
10% neutral-buffered formalin. S-phase cells were labelled with BrdUrd
(60 mg kg-') 30 min before tissue harvest. Sections were processed for
immunohistochemical detection of BrdUrd-labelled nuclei using a specific
antibody for BrdUrd-containing DNA. Labelled and unlabelled crypt cells were
counted in two sections per animal, and the labelling index was determined.
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of 40 Figure 3 Pharmacodynamics of DNA synthesis inhibition (U) and kinetics
of mitotic index (0) in jejunal crypt cells. Mice were given 150 mg kg-' dFdC
and, at 0, 3.5, 6, 12.5, 18, 24, 36 and 48 h after drug administration, jejunum
was harvested and fixed in 10% neutral-buffered formalin. S-phase cells
were labelled with BrdUrd (60 mg kg-') 30 min before tissue harvest.
Sections were processed for immunohistochemical detection of BrdUrd-
labelled nuclei using a specific antibody for BrdUrd-containing DNA.
Labelling and mitotic indices were determined in two transversal jejunal
sections per animal. Each point is an average (± s.e.m.) of three mice
in 1 x PBS for 1 h in a moist 37°C chamber. DNA was denatured
by immersing the slides in 2 N hydrochloric acid (UCB, Brussels,
Belgium). Acid neutralization was done with 0.1 M sodium tetrab-
orate (Sigma Chemical, St Louis, MO, USA). Non-specific
binding was blocked by immersing the slides in 1% bovine serum
albumin (Sigma Chemical) in lxPBS and 7.5% normal horse
serum (Vector Laboratories, Burlingame, CA, USA). Sections
were then incubated first with an anti-BrdUrd BR3 antibody
(Caltag, San Francisco, CA, USA), second with a biotinylated
anti-mouse antibody (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA, USA) and third with horseradish peroxidase-
conjugated avidin (Vectastain ABC kit). Staining was developed
using 3,3'-diaminobenzidine (Sigma Chemical), and sections were
counterstained in haematoxylin.
Determination of the mitotic index
The mitotic index was determined on the sections processed for
detection ofcells with BrdUrd-substituted DNA. Mitotic and non-
mitotic figures were counted on transversal sections of thejejunal
crypts. The mitotic index was determined as the number ofmitotic
cells divided by the total number of cells. Two sections were
scored per mouse. For each time point, three mice were used.
RESULTS
Kinetics of radiosensitization by dFdC on mouse
jejunum
The effect of dFdC on the radiotolerance of mouse jejunum was
studied for various time intervals between drug administration and
irradiation. Radiation effects on mouse jejunum tolerance were
assessed using the crypt survival assay. To avoid drug toxicity, a
single i.p. dFdC dose of 150 mg kg-' was chosen. This dose has
been calculated to be approximately one-tenth of the 10% lethal
dose estimated in C3H mice after single i.p. dose administration
(one dead animal out of seven at 1600 mg kg-' and no lethality at
800 or 400 mg kg-' in eight mice each).
In control mice, the number ofcrypts percircumference reached
122 ± 3.5. In animals treated with dFdC alone (150 mg kg-'), it
reached 122 ± 5.1. For combined dFdC and radiation treatment, a
3-h and a 48-h time interval between drug administration and
irradiation were chosen. As illustrated in Figure 1, in the absence
of dFdC, a radiation dose of 13.70 Gy (confidence interval
13.09-14.84 Gy) was required to induce a level of40 regenerated
crypts per circumference. After dFdC administration, the radiation
dose reached 10.44 (confidence interval 9.88-11.35 Gy) and
15.27 Gy (confidence interval 14.40-16.38 Gy) for a 3-h and a
48-h time interval respectively. Thus, dFdC radiosensitized dose
modification factor (DMF) of 1.3; confidence interval 1.2-
1.4 when given 3 h before irradiation, whereas it slightly radiopro-
tected (DMF of0.9; confidence interval 0.85-0.95) when given 48
h before irradiation. As the slopes of the dose-response relation-
ships for radiation alone and dFdC given 48 h before irradiation
were different, it should be noticed that the protective effect tended
to decrease with lower radiation dose.
Pharmacodynamics of DNA synthesis inhibition and
cell cycle redistribution after dFdC administration
To study the pharmacodynamics of DNA synthesis inhibition by
dFdC in the mouse jejunum crypts, animals were given dFdC and
tissue was harvested from 0 to 48 h after drug administration and
processed for immunohistochemistry analysis. To pulse label S-
phase cells, BrdUrd was administered to the mice 30 min before
tissue harvest.
In untreated mice, the labelling index in the jejunum crypts
reached 26.8 ± 2.0% (Table 1, Figures 2 and 3). As early as 3.5 h
after dFdC administration, DNA synthesis was completely shut off
and remained inhibited for up to at least 6 h. Qualitative analysis
of the tissue sections showed that the crypts contained numerous
figures with the typical morphology of apoptotic bodies, i.e.
shrunken cells with empty space, eosinophilic cytoplasm and
condensed chromatin with nuclear fragments (Figure 2). These
figures were rarely seen after 18 h. Reinitiation of DNA synthesis
took place around 6 h after drug administration. Interestingly,
reinitiation ofDNA synthesis was accompanied by some degree of
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cell synchronization, as illustrated by the oscillating movement of
the labelling index at 12.5, 18, 24 and 36 h after drug administra-
tion. The phenomenon of cell synchronization was further investi-
gated by the kinetics of the mitotic index, which mirrored the
pharmacodynamics of DNA synthesis (Figure 3). At 18 h, the
cohort of synchronized cells probably entered the G2-M phase, as
illustrated by the high mitotic figures, which reached 5.9 ± 2.3%
(Figures 2 and 3).
The study described above demonstrated that 150 mg kg-' dFdC
induced inhibition ofDNA synthesis, which, after an early wave of
apoptosis, recovered at around 6 h with subsequent cell synchro-
nization. It has been reported that dFdC-induced DNA synthesis
inhibition in vitro (Huang et al, 1991) or tumour growth inhibition
in vivo (Hertel et al, 1990) was dependent upon the dose of dFdC
administered. We therefore wanted to determine whether the dura-
tion of DNA synthesis inhibition and cell cycle redistribution in
mouse jejunum crypts could be further increased with a higher
dose of dFdC.
To address this question, mice were treated with 600 mg kg-'
dFdC andjejunum was harvested from 0 to 48 h after drug admin-
istration. As shown in Table 1, neither the degree nor the duration
of DNA synthesis inhibition was dependent on the dose of dFdC.
Apoptotic figures were observed mainly at 3 and 6 h after drug
administration. At 600 mg kg-', the same trend for cell synchro-
nization was also observed as reported at 150 mg kg-'. Thus, no
dose-effect relationship for DNA synthesis inhibition and cell
cycle redistribution in mouse crypt cells was documented for dFdC
dose higher than 150 mg kg-'.
DISCUSSION
The experiments reported here were designed to study the effect of
dFdC on mouse jejunum radiotolerance and to investigate the
association between in vivo radiosensitization and inhibition of
DNA synthesis and cell cycle redistribution. Radiosensitization
(DMF of 1.3) was observed for a 3 h time interval between gem-
citabine administration and radiation and was associated with
DNA synthesis inhibition. As treatment with dFdC alone did not
affect the number of regenerated crypts per circumference, it is
suggested that the observed combined effect results from supra-
additivity. However, as our experiments were not designed to
study the mechanism of interaction between dFdC and radiation,
i.e. to study the influence of dFdC on fractionation sensitivity of
mouse jejunum, one cannot definitely conclude whether the
observed effect results from additivity or supra-additivity.
Moreover, apoptotic figures were observed after treatment with
dFdC alone. Although this effect did not modify the number of
crypts per circumference, one cannot rule out the possibility that
dFdC acted by an independent cell kill mechanism on the same
target cells. For a 48-h time interval betweeii drug administration
and irradiation, a slight radioprotection (DMF of 0.9) was
observed, and this was associated with reinitiation of DNA
synthesis. This slight radioprotection may be explained by accu-
mulation of cells in late S-phase affording some degree of radio-
protection.
In the present study, radiosensitization was only studied at 3 h
and 48 h after dFdC administration. An additional time point for
radiosensitization would be required before one could definitely
conclude that DNA synthesis inhibition and cell cycle redistribu-
tion are indeed surrogates for radiosensitization in vivo. Using a
similar model and end point, a group from MD Anderson Cancer
Center recently reported a DMF of 1.1 for a 1- or 3-h time interval
between single dFdC (50 mg kg-') administration and irradiation.
The DMF reached 1.2 for preirradiation drug exposure times of
6-8 h, and no effect was observed for intervals of 24 or 72 h in
comparison with radiation alone (Elshaikh et al, 1997). The same
group has previously reported that for a single dFdC dose of 10, 50
or 400 mg kg-', DNA synthesis was dramatically inhibited within
3 h in the mouse crypt cells and recovered in a dose-dependent
fashion by 3-9 h (Hittelman et al, 1996). Although comparison
between these data needs to be done cautiously, they also tend to
support the concept that DNA synthesis inhibition is a surrogate
for in vivo radiosensitization of mouse jejunum. Assuming that
this hypothesis is true, one would thus observe radiosensitization
in ourjejunum model for time intervals up to 6 h, and at 18 h when
a substantial number of cells have accumulated in the radiosensi-
tive G2-M phase. On the contrary, one could hypothesize that no
radiosensitization by dFdC (or even a small radioprotection) for
longer time intervals would be observed. In previous studies we
developed the same concept from data previously accumulated
with fludarabine, a purine nucleoside analogue (Gregoire et al,
1994a-c; Gregoire, 1995). In a mouse sarcoma, mouse jejunum
and mouse skin, radiosensitization was observed when DNA
synthesis was completely inhibited or when cells had accumulated
in the G2-M phase. On the contrary, absence of radiosensitization
was accompanied by an absence ofDNA synthesis inhibition. But,
as already stated for dFdC, more data points would also be needed
before a definite conclusion can be drawn on that matter.
The effect of dFdC on mouse tumour growth in vivo (Hertel et
al, 1990; Brakhuis et al, 1995) and on DNA synthesis inhibition in
vitro (Huang et al, 1991) was reported to be dose- and schedule-
dependent. In the present study however, DNA synthesis inhibi-
tion did not differ between dFdC doses of 150 and 600 mg kg-'. As
already mentioned, dFdC is a prodrug that needs to be activated
through successive phosphorylation. The first phosphorylation
step is controlled by the enzyme deoxycytidine kinase (dck),
which has been reported to be the rate-limiting step in the cellular
accumulation ofdFdCTP (Plunkett et al, 1995). Different pharma-
cokinetics ofdFdCTP accumulation have been reported in various
tumour cell lines (Ruiz van Haperen et al, 1994). In some cells,
saturation in dFdCTP accumulation has already been observed for
dFdC concentration of 10 gM whereas, in other cell lines, no satu-
ration has been observed at 100gM dFdC. In human leukaemia
cell lines and in blasts isolated from patients with acute myeloge-
nous leukaemia, saturation of the dck enzyme has been reported
for dFdC concentrations above 20gM and for concentrations
higher than 35 gM, this enzyme was found to be completely inhib-
ited (V. Gandhi, personal communication). In B6C3F mice, the
peak plasma concentration of dFdC was measured at 34.4 jg ml-'
(114 jM) after an i.v. dose of 20 mg kg-' [Eli Lilly, data on file].
The pharmacokinetics of plasmatic dFdC and intracellular
dFdCTP accumulation, as well as the activity ofthe dck enzyme in
the mousejejunum crypt cells is not known. It is however possible
that after a single dFdC dose of 150 mg kg-', dck activity and
consequently dFdCTP accumulation is already saturated in the
mousejejunum.
An important consideration in examining agents that might alter
radiation response is whether the effect is preferentially observed
in tumours as opposed to normal tissues. Typically, a treatment
strategy combining radiotherapy and nucleoside analogues would
bring a therapeutic gain if it increased the effect on tumour while
having minimal or no effect on the normal tissues at risk in the
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irradiated field. In a FaDu human hypopharyngeal tumour gener-
ated in nude mice, enhancements forregrowth delay afterfraction-
ated irradiation have been reported in the range of 1.6-3.3
depending on the dose and schedule of dFdC administration
(Webster et al, 1997). In a SA-NH mouse sarcoma tumour, DMF
for local tumour control reached values between 1.16 and 1.55 for
single dFdC dose of 50 mg kg-' given i.p. from 1 to 72 h before
single-dose irradiation (Fujii et al, 1997). The larger enhancement
was obtained when the drug was given 24 h before irradiation.
Comparison of our present data on mouse jejunum with these
published data on tumour models tends to indicate that a thera-
peutic gain might be obtained especially for a long time interval
between drug administration and irradiation. Similar conclusions
were drawn from comparisons between tumour effect and skin
reaction or late leg fibrosis (Fujii et al, 1997). In clinical situations,
however, radiotherapy is usually delivered on a daily fractionated
schedule. Data comparing tumour effect and normal tissue toxicity
after fractionated irradiation are thus needed before definite
conclusions can be drawn on the therapeutic gain ofthe combined
treatment. The reason for the differential radiosensitization effect
of dFdC is not known. Differences in pharmacokinetics of
dFdCTP accumulation and retention, differences in cell prolifera-
tion and differences in the physiopathology of radiation-induced
cell injury may account for the differential effects observed
between tumours and normal tissues. Previous findings with
fludarabine have identified the differences in pharmacodynamics
ofDNA synthesis inhibition (assumed to reflect differences in the
pharmacokinetics ofdrug metabolism) between normal tissues and
tumours as being some ofthe factors associated with differences in
the kinetics of radiosensitization (Gregoire et al., 1994a-c;
Gregoire, 1995]. Subsequently, we have recently started a phase I
clinical trial combining radiotherapy and fludarabine in locally
advanced head and neck squamous cell carcinomas, in which a
comparative determination of the pharmacodynamics of DNA
synthesis inhibition will be performed in tumour and normal
mucosa. A European phase I trial combining dFdC and radio-
therapy for stage IIIB non-small-cell lung cancerhas recently been
started. A study on DNA synthesis inhibition in skin and oral
mucosa is also foreseen.
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